Accendra Health, Inc. received a New York Stock Exchange notice on October 27, 2026, stating that it is not in compliance with the exchange’s continued-listing standard. The standard requires average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders’ equity of not less than $50.0 million. The notice does not immediately delist the company’s common stock.
Accendra intends to notify the NYSE within 10 business days of receipt that it will submit a business plan. It has 45 calendar days after receipt to submit a plan demonstrating how it intends to regain compliance within 18 months of receipt. The NYSE will review the plan; if accepted, the company will be subject to quarterly monitoring of its progress. Its common stock will continue to be listed and trade on the NYSE during this period, subject to other continued-listing requirements. The notice does not affect Accendra’s business, operations, or SEC reporting obligations.
Accendra Health (ACH) is asking shareholders to authorize a 1-for-20 to 1-for-30 reverse stock split, with the final ratio and whether and when to implement it left to the Board after approval. The proposal also reduces authorized common shares by the corresponding ratio. The Board may abandon the proposal before its effective date.
Accendra Health says it received NYSE notice on October 6, 2026, because its average closing price was below $1.00 per share over a consecutive 30 trading-day period. It has six months to regain compliance. Shareholders will vote virtually on December 1, 2026. As of October 27, 2026, 76,965,322 common shares were outstanding; failure to regain compliance could lead to delisting proceedings.
Accendra Health (ACH) is asking shareholders to approve an amendment authorizing a reverse split of common stock at a ratio from 1-for-20 to 1-for-30; the Board would select the final ratio. The proposal also reduces authorized common shares by a corresponding ratio. The Board may decide whether and when to implement the split and may abandon it before its effective date, even after shareholder approval. The company is authorized to issue 200,000,000 common shares.
The proposal follows an October 6, 2026 NYSE notice that Accendra Health’s average closing share price was below $1.00 over a consecutive 30-trading-day period. The company has six months from the notice to regain compliance and says a reverse split is one of several options it intends to pursue. If it does not regain compliance, the NYSE will commence delisting proceedings. Accendra Health says the split is intended to raise the per-share price, but states there is no assurance the split will increase the stock price. The Board unanimously recommends voting FOR both the reverse-split proposal and a separate adjournment proposal, which would permit additional proxy solicitation if votes are insufficient.
Accendra Health (ACH) received a New York Stock Exchange notice on October 6, 2026, after its common stock’s average closing price was below $1.00 per share over a consecutive 30 trading-day period. The notice does not immediately affect the stock’s NYSE listing.
Accendra Health has six months after receiving the notice to regain compliance and intends to tell the NYSE within 10 business days that it will seek to cure the deficiency. It may regain compliance if, on the last trading day of a calendar month during the cure period or on its final day, the stock closes at least $1.00 and has an average closing price of at least $1.00 over the 30 trading-day period ending that day. The company is considering alternatives, including, if necessary, a reverse stock split subject to stockholder approval no later than its next annual meeting, anticipated in May 2027. Its stock remains listed during the period, subject to other NYSE continued listing standards.
Accendra Health Inc. is the issuer named in a Schedule 13G in which Bank of America Corporation reported beneficial ownership of 8,270,614 common shares, representing 10.8% of the class, as of September 30, 2026. It reported shared voting power over 1,349,537 shares and shared dispositive power over 8,270,614 shares, with no sole voting or dispositive power.
Bank of America Corporation filed on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., Bank of America, N.A., Merrill Lynch International, and Merrill Lynch Pierce Fenner & Smith, Inc.
Accendra Health Inc. President & CEO and director Kenneth Gardner-Smith acquired 283,554 shares of common stock in a restricted stock grant on October 5, 2026. The grant vests one-third per year over three years. Gardner-Smith’s reported direct holdings following the grant were 369,667 shares.
Accendra Health, Inc. said Kenneth Gardner-Smith and the company mutually agreed that he will begin as President and Chief Executive Officer on October 5, 2026. Edward A. Pesicka will remain in the role until Gardner-Smith assumes it, then retire from the Board of Directors. Under a consulting agreement dated September 28, 2026, Pesicka will advise the company for up to 30 months; his previously awarded outstanding equity awards will continue to vest under their existing terms during the arrangement, and he will receive a COBRA benefit.
Accendra Health Inc. (ACH) EVP & CFO Leon Jonathan A reported 4,265 shares surrendered to the issuer on September 23, 2026, to satisfy tax-withholding obligations in connection with vesting of restricted stock. The reported price was $0.85 per share, and he held 286,268 shares directly following the transaction. No Rule 10b5-1 plan is reported.
Accendra Health, Inc. (ACH) announced a leadership transition, naming Kenneth Gardner-Smith as its next President and Chief Executive Officer, expected to assume the role early in the fourth quarter of 2026. He succeeds Edward A. Pesicka, who will retire as CEO and from the Board and then serve as an advisor to support a smooth transition.
Under an offer letter dated September 16, 2026, Gardner-Smith will receive a $1,000,000 base salary, be eligible for a target annual cash bonus equal to 130% of base salary (prorated for 2026), and a long-term incentive grant with a target value of $6,000,000, split among restricted stock units, stock-settled PSUs, and cash-settled PSUs. He is also granted a $650,000 sign-on cash bonus and $2,000,000 in cash-settled stock appreciation rights vesting over three years. The company also created and filled a new Chief Commercial Officer role, appointing Scott Lloyd effective October 5, 2026 to unify commercial strategy and growth efforts.
Accendra Health, Inc. (ACH) is the issuer for a planned resale of common stock disclosed by Coliseum Capital Management, LLC, a 10% stockholder, under Rule 144. Coliseum and an investment advisory client of Coliseum Capital Management together intend to sell up to 10,726,759 shares of Accendra Health common stock through JonesTrading Institutional Services LLC and Virtu Americas LLC.
The filing states an aggregate market value for the shares of $11,584,899.72 and notes that Accendra Health had 76,904,704 shares outstanding. The securities being sold were acquired in open market purchases made for cash, with acquisition dates commencing on July 31, 2024 and ceasing on August 14, 2025.